|
Categories |
|
Oncology |
|
|
Biotechnology
Cancer
Consumer
Customer
Relationship Management
Drug
Delivery
eHealthcare
Pharma
eHealthcare
Physician
Generics
Healthcare
Medical
Devices
OTC
Pharmaceuticals
Pharmaceuticals
Pharmacoeconomics
Therapeutic
Areas:
- Cardiovascular
- Central
Nervous System
- Immune
Disorders and Inflammation
- Infectious
Diseases
- Oncology
-
Women'sHealth
|
|
|
1- Myelodysplastic Syndrome - An underserved population offers commercial opportunity 18-Oct-2005
Key issues in the treatment of myelodysplastic syndrome including epidemiology, current treatment controversies, physician prescribing trends, unmet needs, and profiles of promising late stage candidates in the development pipeline.
------------------------------------------------------------------------------------------------------------------------- |
2- Stakeholder Insight: Prostate Cancer - A Prostrate Market Waiting for Innovations 11-Oct-2005
Explores current treatment practices for hormone-sensitive and hormone-refractory prostate cancer in the seven major markets, based on primary research with 180 physicians, and examines key pipeline agents and potential regimens in 2010.
------------------------------------------------------------------------------------------------------------------------- |
3- Stakeholder Opinions: Chronic Leukemias - Curative Intent Raises the Bar 07-Oct-2005
Key issues in chronic leukemia pharmacotherapy, including unmet needs, current treatment controversies, advancements in risk-stratification and prognostication, and novel therapies in the developmental pipeline.
------------------------------------------------------------------------------------------------------------------------- |
4- Commercial Insight: Innovative Targeted Therapies - 'Smart Drugs' on Target for Increasing Growth 4-Oct-2005
Analysis of the current and future potential of the targeted therapies market. Includes in-depth profiles of the late-phase pipeline, strategic recommendations and forecasts to 2014 for key products across the seven major pharmaceutical markets.
------------------------------------------------------------------------------------------------------------------------- |
5- Optimizing Targeted Treatment in Cancer: Negotiating the Challenges to Success 02-Sep-2005
Drawing on the ideas and discussion generated by leading oncology experts, this Market Brief examines the clinical and commercial challenges facing developers, and strategies to meet them as the oncology market transitions into a new era.
------------------------------------------------------------------------------------------------------------------------- |
6- Commercial Insight: Cytotoxics - Generic Adversity Facing Major Cytotoxics 19-Jul-2005
Explores the current and future market dynamics of major cytotoxics, including sales forecasts and key events to 2014 in the seven major pharmaceutical markets.
------------------------------------------------------------------------------------------------------------------------- |
7- Commercial Insight: Antihormonal Therapies Aromatase Inhibitors Reinvigorate a Mature Market 08-Jul-2005
Analysis of the current and future potential of the antihormonal therapies market. Includes sales forecasts to 2014 across the seven major pharmaceutical markets in light of key events predicted to influence product revenues.
------------------------------------------------------------------------------------------------------------------------- |
8- Stakeholder Opinions: Primary Brain Cancer - Temozolomide Turns Heads 06-Jul-2005
Key issues surrounding the glioma market including epidemiology data, current treatment controversies, unmet needs, economic issues associated with therapy and profiles of agents in the developmental pipeline.
------------------------------------------------------------------------------------------------------------------------- |
9- Market Leaders in Oncology 2004 - Roche and
Genentech Continue to Blaze a Trail
6-Jan-2005
Current and future trends in the oncology sector,
including strengths and weaknesses of the market leaders in the
oncology sector, R&D activity, M&A opportunities and
licensing deals.
-------------------------------------------------------------------------------------------------------------------------
|
10- Stakeholder Opinions: Brain Metastases - Turning
Prolonged Survival on its Head? 15-Dec-2004
Key issues in the brain metastases
market including detailed epidemiology data, treatment
controversies, profile of agents in the developmental pipeline and
the potential use of targeted therapy in brain metastasis in
combination with radiotherapy.
-------------------------------------------------------------------------------------------------------------------------
|
11- Molecular-Targeted Pharmacotherapy in Myeloma:
Clinical and Strategic Challenges on the Road to
Commercialization 13-July-2004
Key issues in myeloma
pharmacotherapy, including current treatment controversies, novel
myeloma-targeted therapies in the developmental pipeline, and
clinical, regulatory and pharmacoeconomic challenges on the path to
commercialization
-------------------------------------------------------------------------------------------------------------------------
|
12- Stakeholder Opinions: Malignant Melanoma - High
Hurdles, High Rewards, Are Vaccines Only Skin Deep?
16-Apr-2004
Key issues in the malignant melanoma market, including
current diagnosis and treatment patterns, insight into pipeline
drugs, and stakeholder opinions .
-------------------------------------------------------------------------------------------------------------------------
|
13- Commercial Perspectives: Cytotoxics - Third-Generation
Cytotoxics To Offset Taxol’s Generic Woes 9-Mar-2004
Key issues in the cytotoxic market including profiles
of key cytotoxic drugs, their sales forecasts to 2011, and lifecycle
and portfolio management of cytotoxic products.
-------------------------------------------------------------------------------------------------------------------------
|
14- Commercial Perspectives: Anti-Hormonals - Tamoxifen to
be Obsolete by 2010? 5-Feb-2004
In-depth
analysis of the cancer anti-hormonals market in 2002 and the future
potential of the market to 2011.
-------------------------------------------------------------------------------------------------------------------------
|
15- Casodex 150mg - What now for AstraZeneca’s prostate
cancer product?
23-Dec-2003
An
in-depth analysis of the withdrawal of Casodex 150mg for the
treatment of localized prostate
cancer.
-------------------------------------------------------------------------------------------------------------------------
|
16- ECCO12 Highlights - Chemotherapies in Major Tumors
21-Nov-2003
Highlights of the major issues in breast, non-small
cell lung and colorectal cancer covered at the 12th meeting of ECCO
in September 2003.
-------------------------------------------------------------------------------------------------------------------------
|
17- Glioblastoma Review - Temodar partnering pipeline
drugs 10-Sep-2003
Overview of current
treatment modalities and analysis of drugs in development for
glioblastoma.
-------------------------------------------------------------------------------------------------------------------------
|
18- Benign Prostatic Hyperplasia: Expanding the drug
treated population
4-Jun-2003
Analysis of
the current and future trends in the BPH market.
-------------------------------------------------------------------------------------------------------------------------
|
19- Stakeholder Insight: Herceptin, The First of the
Innovative Therapies
2-Jun-2003
Assessment
of physician opinion on the use of Herceptin in breast cancer, and
recommendations to overcome the barriers to its
prescription.
-------------------------------------------------------------------------------------------------------------------------
|
20- Strategic Perspectives: Non-Hodgkin’s
Lymphoma
A
Market Galvanized by the Advent of Innovative Therapies
25-Mar-2003
In-depth analysis of current treatment regimens and
agents in development for non-Hodgkin’s lymphoma, and forecast sales
to
2010.
-------------------------------------------------------------------------------------------------------------------------
|
21-Stakeholder Opinions: Renal Cell Carcinoma – A Gateway
for Angiogenesis Inhibitors? 17-Mar-2003
Current treatment patterns and key pipeline drugs in
the renal cell carcinoma
market.
-------------------------------------------------------------------------------------------------------------------------
|
22-Multiple Myeloma update with ASH highlights -
Increasing the Therapeutic Option 30-Jan-2003
Currently available therapies for multiple myeloma is
effective in high dose, but is associated with severe toxicity. In
addition, all patients eventually relapse. This has resulted in a
market ready for the entry of low toxicity therapies and drugs that
will increase response rates and maintain
remission.
------------------------------------------------------------------------------------------------------------------------ |
23-Market Dynamics: Anti-hormonal Therapies - Positioning
for a Changing Paradigm 21-Jan-2003
Strategies for success in a market set for
change.
------------------------------------------------------------------------------------------------------------------------ |
| |
| |
